Thermo Fisher Scientific, Inc.

Equities

TMO

US8835561023

Advanced Medical Equipment & Technology

Market Closed - Nyse Other stock markets 04:00:02 2026-02-13 pm EST			5-day change	1st Jan Change
504.82 ^USD	-0.98%		-7.00%	-12.88%

Feb. 11	Thermo Fisher Scientific Expands Real-World Data Interoperability and Linkage Through Strategic Collaboration with Datavant	CI
Feb. 11	Thermo Fisher Collaborates With Datavant to Link Real-World Data With Clinical Research	MT

Henry Schein, Inc. Announces Management Changes

Published on 01/12/2026 at 01:56 pm EST

S&P Capital IQ

THERMO FISHER SCIENTIFIC, INC.

-0.98%

Thermo Fisher Scientific Inc. announced that Michel Lagarde, Executive Vice President and Chief Operating Officer, and Frederick M. Lowery, Executive Vice President, have decided to leave the Company to pursue other opportunities. Mr. Lagarde will depart on March 31, 2026, and Mr. Lowery will depart on February 28, 2026. Effective March 1, 2026, the Company will update its organizational structure and leadership team.

Marc N. Casper will become Chairman and Chief Executive Officer. Gianluca Pettiti, currently an Executive Vice President, will be promoted and transition to the role of President and Chief Operating Officer. Additionally, Michael Shafer, currently an Executive Vice President, will be promoted to an expanded role and will report directly to the Chief Executive Officer.

Latest news about Thermo Fisher Scientific, Inc.

Feb. 11	Thermo Fisher Scientific Expands Real-World Data Interoperability and Linkage Through Strategic Collaboration with Datavant	CI
Feb. 11	Thermo Fisher Collaborates With Datavant to Link Real-World Data With Clinical Research	MT
Feb. 10	Thermo Fisher Scientific Prices $3.8 Billion Senior Notes	MT
Feb. 10	Thermo Fisher Scientific Prices Offering of USD-Denominated Senior Notes	CI
Feb. 09	Thermo Fisher Scientific says prices $3.8 bln offering of USD-denominated senior notes	RE
Feb. 09	Thermo Fisher Scientific files pricing term sheet for $3.8 billion four part senior notes offering	RE
Feb. 09	Thermo Fisher Scientific Inc files for four-part senior notes offering size not disclosed	RE
Feb. 05	Microsoft-Backed OpenAI Launches Frontier Platform to Manage Enterprise AI Agents	MT
Feb. 05	IQVIA forecasts weak annual profit on higher interest expenses	RE
Feb. 05	IXICO plc Appoints Tanya Voloshen as Chief Commercial Officer	CI
Feb. 04	Biotech firm Bio-Techne beats quarterly estimates on strength in key unit	RE
Feb. 02	Revvity forecasts 2026 profit, revenue above estimates after blowout fourth quarter	RE
Jan. 30	UBS Adjusts Price Target on Thermo Fisher Scientific to $615 From $590, Maintains Neutral Rating	MT
Jan. 30	Raymond James Adjusts Price Target on Thermo Fisher Scientific to $670 From $630, Maintains Outperform Rating	MT
Jan. 30	Baird Adjusts Price Target on Thermo Fisher Scientific to $653 From $645, Maintains Outperform Rating	MT

Chart Thermo Fisher Scientific, Inc.

Duration

Period

TMO: Dynamic Chart

Company Profile

Thermo Fisher Scientific Inc. specializes in the design, manufacturing and marketing of laboratory and scientific equipments. Net sales (including intragroup) break down by family of products as follows: - laboratory equipments (73.2%). Moreover, the group proposes chemical products (reagents, solvent, salts, etc.), consumable products (tubes, funnels, vials, etc.), as well as conditioning, warehousing, storage, etc.; - scientific analysis equipments (16.7%): analyzer (of water, gas, grounds, etc.), mass spectrometers, molecular spectroscopes, microscopes, manometers, samplers, microbiology equipments, reactive agents, etc.; - diagnostics equipment and products (10.1%). Net sales break down by source of revenue between sales of products (58.4%) and services (41.6%). Net sales break down geographically as follows: North America (52.5%), Europe (25.3%), Asia/Pacific (18.6%) and other (3.6%).

Employees

125,000

Sector

Advanced Medical Equipment & Technology

Calendar

Apr. 28 - Q1 2026 Earnings Release (Projected)

More about the company